Braveheart Bio (NASDAQ:BRVE) Reaches New 52-Week Low - Time to Sell?

Key Points

• Braveheart Bio shares fell to a new 52-week low of $19.83 and were last down 2.8% at $21.23, below the 50-day moving average of $26.03.
• Despite the decline, analysts remain broadly optimistic, with five Buy ratings and one Hold rating producing a “Moderate Buy” consensus and an average price target of $45.25.
• The company reported a significant quarterly loss of $2.51 per share versus the expected $0.25 loss. Meanwhile, insiders purchased 8.75 million shares worth approximately $157.5 million over the past 90 days, signaling confidence from major holders and directors.

Shares of Braveheart Bio, Inc. (NASDAQ:BRVE - Get Free Report) reached a new 52-week low during trading on Monday. The company traded as low as $19.83 and last traded at $21.2280, with a volume of 168546 shares changing hands. The stock had previously closed at $21.27.

Analyst Upgrades and Downgrades

Several research firms have weighed in on BRVE. Cantor Fitzgerald initiated coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set an "overweight" rating and a $40.00 price objective on the stock. The Goldman Sachs Group assumed coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set a "buy" rating and a $48.00 price objective on the stock. TD Cowen started coverage on Braveheart Bio in a research note on Monday, August 31st. They set a "buy" rating for the company. Stifel Nicolaus initiated coverage on shares of Braveheart Bio in a report on Monday, August 31st. They set a "buy" rating and a $45.00 price target for the company. Finally, Zacks Research raised shares of Braveheart Bio to a "hold" rating in a research report on Tuesday, September 1st. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $45.25.

Braveheart Bio Stock Down 2.8%

The stock has a 50 day simple moving average of $26.03.

Braveheart Bio (NASDAQ:BRVE - Get Free Report) last issued its quarterly earnings data on Tuesday, September 8th. The company reported ($2.51) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($2.26). As a group, equities research analysts expect that Braveheart Bio, Inc. will post -1.48 EPS for the current fiscal year.

Insider Transactions at Braveheart Bio

In other news, Director David Lubner acquired 55,555 shares of the company's stock in a transaction on Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, with a total value of $999,990.00. Following the acquisition, the director owned 55,555 shares of the company's stock, valued at $999,990. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Bio Fund Iv L.P. Ah purchased 1,100,000 shares of the business's stock in a transaction dated Friday, August 7th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $19,800,000.00. Following the purchase, the insider owned 10,232,420 shares in the company, valued at $184,183,560. This trade represents a 12.05% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders acquired 8,751,942 shares of company stock valued at $157,534,956.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.